Click for best price
Cancer Antibody Drug Conjugates Market Size, Share 2022
Market Analysis and Insights: Global Cancer Antibody Drug Conjugates Market
The global Cancer Antibody Drug Conjugates market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cancer Antibody Drug Conjugates market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Cancer Antibody Drug Conjugates market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Cancer Antibody Drug Conjugates market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cancer Antibody Drug Conjugates market.
Global Cancer Antibody Drug Conjugates Scope and Market Size
Cancer Antibody Drug Conjugates market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Cancer Antibody Drug Conjugates market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Cancer Antibody Drug Conjugates market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
First & Second Generation ADCs
Third Generation ADCs
Segment by Application
Hospitals
Clinics
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Novartis
Merck
Roche
AbbVie
UCB
Bristol-Myers Squibb
Stem CentRx
Biogen Idec
Nordic Nanovector
Millennium
Biotest AG
PDL BioPharma
Progenics Pharmaceuticals
Seattle Genetics
Viventia Biotechnologies
AbGenomics Corporation
Helix BioPharma
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes Cancer Antibody Drug Conjugates product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of Cancer Antibody Drug Conjugates, with price, sales, revenue, and global market share of Cancer Antibody Drug Conjugates from 2019 to 2022.
Chapter 3, the Cancer Antibody Drug Conjugates competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Cancer Antibody Drug Conjugates breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Cancer Antibody Drug Conjugates market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Cancer Antibody Drug Conjugates.
Chapter 13, 14, and 15, to describe Cancer Antibody Drug Conjugates sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 Cancer Antibody Drug Conjugates Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
Report Attributes |
Report Details |
Report Title |
Global and United States Cancer Antibody Drug Conjugates Market Report & Forecast 2022-2028 |
Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
Base Year |
2021 |
Forecast Year |
2029 |
Number of Pages |
113 Pages |
Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Study Coverage
1.1 Cancer Antibody Drug Conjugates Product Introduction
1.2 Global Cancer Antibody Drug Conjugates Outlook 2017 VS 2022 VS 2028
1.2.1 Global Cancer Antibody Drug Conjugates Sales in US$ Million for the Year 2017-2028
1.2.2 Global Cancer Antibody Drug Conjugates Sales in Volume for the Year 2017-2028
1.3 United States Cancer Antibody Drug Conjugates Outlook 2017 VS 2022 VS 2028
1.3.1 United States Cancer Antibody Drug Conjugates Sales in US$ Million for the Year 2017-2028
1.3.2 United States Cancer Antibody Drug Conjugates Sales in Volume for the Year 2017-2028
1.4 Cancer Antibody Drug Conjugates Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Cancer Antibody Drug Conjugates in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Cancer Antibody Drug Conjugates Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Cancer Antibody Drug Conjugates Market Dynamics
1.5.1 Cancer Antibody Drug Conjugates Industry Trends
1.5.2 Cancer Antibody Drug Conjugates Market Drivers
1.5.3 Cancer Antibody Drug Conjugates Market Challenges
1.5.4 Cancer Antibody Drug Conjugates Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Cancer Antibody Drug Conjugates Market Segment by Type
2.1.1 First & Second Generation ADCs
2.1.2 Third Generation ADCs
2.2 Global Cancer Antibody Drug Conjugates Market Size by Type
2.2.1 Global Cancer Antibody Drug Conjugates Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Cancer Antibody Drug Conjugates Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Cancer Antibody Drug Conjugates Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Cancer Antibody Drug Conjugates Market Size by Type
2.3.1 United States Cancer Antibody Drug Conjugates Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Cancer Antibody Drug Conjugates Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Cancer Antibody Drug Conjugates Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Cancer Antibody Drug Conjugates Market Segment by Application
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Others
3.2 Global Cancer Antibody Drug Conjugates Market Size by Application
3.2.1 Global Cancer Antibody Drug Conjugates Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Cancer Antibody Drug Conjugates Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Cancer Antibody Drug Conjugates Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Cancer Antibody Drug Conjugates Market Size by Application
3.3.1 United States Cancer Antibody Drug Conjugates Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Cancer Antibody Drug Conjugates Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Cancer Antibody Drug Conjugates Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Cancer Antibody Drug Conjugates Competitor Landscape by Company
4.1 Global Cancer Antibody Drug Conjugates Market Size by Company
4.1.1 Top Global Cancer Antibody Drug Conjugates Manufacturers Ranked by Revenue (2021)
4.1.2 Global Cancer Antibody Drug Conjugates Revenue by Manufacturer (2017-2022)
4.1.3 Global Cancer Antibody Drug Conjugates Sales by Manufacturer (2017-2022)
4.1.4 Global Cancer Antibody Drug Conjugates Price by Manufacturer (2017-2022)
4.2 Global Cancer Antibody Drug Conjugates Concentration Ratio (CR)
4.2.1 Cancer Antibody Drug Conjugates Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Cancer Antibody Drug Conjugates in 2021
4.2.3 Global Cancer Antibody Drug Conjugates Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Cancer Antibody Drug Conjugates Manufacturing Base Distribution, Product Type
4.3.1 Global Cancer Antibody Drug Conjugates Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Cancer Antibody Drug Conjugates Product Type
4.3.3 Date of International Manufacturers Enter into Cancer Antibody Drug Conjugates Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Cancer Antibody Drug Conjugates Market Size by Company
4.5.1 Top Cancer Antibody Drug Conjugates Players in United States, Ranked by Revenue (2021)
4.5.2 United States Cancer Antibody Drug Conjugates Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Cancer Antibody Drug Conjugates Sales by Players (2020, 2021 & 2022)
5 Global Cancer Antibody Drug Conjugates Market Size by Region
5.1 Global Cancer Antibody Drug Conjugates Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Cancer Antibody Drug Conjugates Market Size in Volume by Region (2017-2028)
5.2.1 Global Cancer Antibody Drug Conjugates Sales in Volume by Region: 2017-2022
5.2.2 Global Cancer Antibody Drug Conjugates Sales in Volume Forecast by Region (2023-2028)
5.3 Global Cancer Antibody Drug Conjugates Market Size in Value by Region (2017-2028)
5.3.1 Global Cancer Antibody Drug Conjugates Sales in Value by Region: 2017-2022
5.3.2 Global Cancer Antibody Drug Conjugates Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Cancer Antibody Drug Conjugates Market Size YoY Growth 2017-2028
6.1.2 North America Cancer Antibody Drug Conjugates Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Cancer Antibody Drug Conjugates Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Cancer Antibody Drug Conjugates Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Cancer Antibody Drug Conjugates Market Size YoY Growth 2017-2028
6.3.2 Europe Cancer Antibody Drug Conjugates Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Cancer Antibody Drug Conjugates Market Size YoY Growth 2017-2028
6.4.2 Latin America Cancer Antibody Drug Conjugates Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Cancer Antibody Drug Conjugates Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Cancer Antibody Drug Conjugates Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Novartis
7.1.1 Novartis Corporation Information
7.1.2 Novartis Description and Business Overview
7.1.3 Novartis Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Novartis Cancer Antibody Drug Conjugates Products Offered
7.1.5 Novartis Recent Development
7.2 Merck
7.2.1 Merck Corporation Information
7.2.2 Merck Description and Business Overview
7.2.3 Merck Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Merck Cancer Antibody Drug Conjugates Products Offered
7.2.5 Merck Recent Development
7.3 Roche
7.3.1 Roche Corporation Information
7.3.2 Roche Description and Business Overview
7.3.3 Roche Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Roche Cancer Antibody Drug Conjugates Products Offered
7.3.5 Roche Recent Development
7.4 AbbVie
7.4.1 AbbVie Corporation Information
7.4.2 AbbVie Description and Business Overview
7.4.3 AbbVie Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
7.4.4 AbbVie Cancer Antibody Drug Conjugates Products Offered
7.4.5 AbbVie Recent Development
7.5 UCB
7.5.1 UCB Corporation Information
7.5.2 UCB Description and Business Overview
7.5.3 UCB Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
7.5.4 UCB Cancer Antibody Drug Conjugates Products Offered
7.5.5 UCB Recent Development
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Corporation Information
7.6.2 Bristol-Myers Squibb Description and Business Overview
7.6.3 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Products Offered
7.6.5 Bristol-Myers Squibb Recent Development
7.7 Stem CentRx
7.7.1 Stem CentRx Corporation Information
7.7.2 Stem CentRx Description and Business Overview
7.7.3 Stem CentRx Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Stem CentRx Cancer Antibody Drug Conjugates Products Offered
7.7.5 Stem CentRx Recent Development
7.8 Biogen Idec
7.8.1 Biogen Idec Corporation Information
7.8.2 Biogen Idec Description and Business Overview
7.8.3 Biogen Idec Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Biogen Idec Cancer Antibody Drug Conjugates Products Offered
7.8.5 Biogen Idec Recent Development
7.9 Nordic Nanovector
7.9.1 Nordic Nanovector Corporation Information
7.9.2 Nordic Nanovector Description and Business Overview
7.9.3 Nordic Nanovector Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Nordic Nanovector Cancer Antibody Drug Conjugates Products Offered
7.9.5 Nordic Nanovector Recent Development
7.10 Millennium
7.10.1 Millennium Corporation Information
7.10.2 Millennium Description and Business Overview
7.10.3 Millennium Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Millennium Cancer Antibody Drug Conjugates Products Offered
7.10.5 Millennium Recent Development
7.11 Biotest AG
7.11.1 Biotest AG Corporation Information
7.11.2 Biotest AG Description and Business Overview
7.11.3 Biotest AG Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Biotest AG Cancer Antibody Drug Conjugates Products Offered
7.11.5 Biotest AG Recent Development
7.12 PDL BioPharma
7.12.1 PDL BioPharma Corporation Information
7.12.2 PDL BioPharma Description and Business Overview
7.12.3 PDL BioPharma Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
7.12.4 PDL BioPharma Products Offered
7.12.5 PDL BioPharma Recent Development
7.13 Progenics Pharmaceuticals
7.13.1 Progenics Pharmaceuticals Corporation Information
7.13.2 Progenics Pharmaceuticals Description and Business Overview
7.13.3 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Progenics Pharmaceuticals Products Offered
7.13.5 Progenics Pharmaceuticals Recent Development
7.14 Seattle Genetics
7.14.1 Seattle Genetics Corporation Information
7.14.2 Seattle Genetics Description and Business Overview
7.14.3 Seattle Genetics Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Seattle Genetics Products Offered
7.14.5 Seattle Genetics Recent Development
7.15 Viventia Biotechnologies
7.15.1 Viventia Biotechnologies Corporation Information
7.15.2 Viventia Biotechnologies Description and Business Overview
7.15.3 Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
7.15.4 Viventia Biotechnologies Products Offered
7.15.5 Viventia Biotechnologies Recent Development
7.16 AbGenomics Corporation
7.16.1 AbGenomics Corporation Corporation Information
7.16.2 AbGenomics Corporation Description and Business Overview
7.16.3 AbGenomics Corporation Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
7.16.4 AbGenomics Corporation Products Offered
7.16.5 AbGenomics Corporation Recent Development
7.17 Helix BioPharma
7.17.1 Helix BioPharma Corporation Information
7.17.2 Helix BioPharma Description and Business Overview
7.17.3 Helix BioPharma Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2017-2022)
7.17.4 Helix BioPharma Products Offered
7.17.5 Helix BioPharma Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Cancer Antibody Drug Conjugates Industry Chain Analysis
8.2 Cancer Antibody Drug Conjugates Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Cancer Antibody Drug Conjugates Distributors
8.3 Cancer Antibody Drug Conjugates Production Mode & Process
8.4 Cancer Antibody Drug Conjugates Sales and Marketing
8.4.1 Cancer Antibody Drug Conjugates Sales Channels
8.4.2 Cancer Antibody Drug Conjugates Distributors
8.5 Cancer Antibody Drug Conjugates Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Cancer Antibody Drug Conjugates CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Cancer Antibody Drug Conjugates Market Trends
Table 3. Cancer Antibody Drug Conjugates Market Drivers
Table 4. Cancer Antibody Drug Conjugates Market Challenges
Table 5. Cancer Antibody Drug Conjugates Market Restraints
Table 6. Global Cancer Antibody Drug Conjugates Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Cancer Antibody Drug Conjugates Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Cancer Antibody Drug Conjugates Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Cancer Antibody Drug Conjugates Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Cancer Antibody Drug Conjugates Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Cancer Antibody Drug Conjugates Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Cancer Antibody Drug Conjugates Revenue Share by Manufacturer, 2017-2022
Table 13. Global Cancer Antibody Drug Conjugates Sales by Manufacturer, (K Pcs), 2017-2022
Table 14. Global Cancer Antibody Drug Conjugates Sales Share by Manufacturer, 2017-2022
Table 15. Global Cancer Antibody Drug Conjugates Price by Manufacturer (2017-2022) & (USD/Pcs)
Table 16. Global Cancer Antibody Drug Conjugates Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Cancer Antibody Drug Conjugates by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Antibody Drug Conjugates as of 2021)
Table 18. Top Players of Cancer Antibody Drug Conjugates in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Cancer Antibody Drug Conjugates Product Type
Table 20. Date of International Manufacturers Enter into Cancer Antibody Drug Conjugates Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Cancer Antibody Drug Conjugates Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Cancer Antibody Drug Conjugates Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Cancer Antibody Drug Conjugates Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Cancer Antibody Drug Conjugates Sales by Players, (K Pcs), 2020, 2021 & 2022
Table 26. United States Cancer Antibody Drug Conjugates Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Cancer Antibody Drug Conjugates Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Cancer Antibody Drug Conjugates Sales in Volume by Region (2017-2022) & (K Pcs)
Table 29. Global Cancer Antibody Drug Conjugates Sales in Volume Forecast by Region (2023-2028) & (K Pcs)
Table 30. Global Cancer Antibody Drug Conjugates Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Cancer Antibody Drug Conjugates Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Cancer Antibody Drug Conjugates Sales in Volume by Country (2017-2028) & (K Pcs)
Table 33. North America Cancer Antibody Drug Conjugates Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Cancer Antibody Drug Conjugates Sales in Volume by Region (2017-2028) & (K Pcs)
Table 35. Asia Pacific Cancer Antibody Drug Conjugates Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Cancer Antibody Drug Conjugates Sales in Volume by Country (2017-2028) & (K Pcs)
Table 37. Europe Cancer Antibody Drug Conjugates Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Cancer Antibody Drug Conjugates Sales in Volume by Country (2017-2028) & (K Pcs)
Table 39. Latin Americaa Cancer Antibody Drug Conjugates Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Cancer Antibody Drug Conjugates Sales in Volume by Country (2017-2028) & (K Pcs)
Table 41. Middle East and Africa Cancer Antibody Drug Conjugates Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Novartis Corporation Information
Table 43. Novartis Description and Business Overview
Table 44. Novartis Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 45. Novartis Cancer Antibody Drug Conjugates Product
Table 46. Novartis Recent Development
Table 47. Merck Corporation Information
Table 48. Merck Description and Business Overview
Table 49. Merck Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 50. Merck Product
Table 51. Merck Recent Development
Table 52. Roche Corporation Information
Table 53. Roche Description and Business Overview
Table 54. Roche Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 55. Roche Product
Table 56. Roche Recent Development
Table 57. AbbVie Corporation Information
Table 58. AbbVie Description and Business Overview
Table 59. AbbVie Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 60. AbbVie Product
Table 61. AbbVie Recent Development
Table 62. UCB Corporation Information
Table 63. UCB Description and Business Overview
Table 64. UCB Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 65. UCB Product
Table 66. UCB Recent Development
Table 67. Bristol-Myers Squibb Corporation Information
Table 68. Bristol-Myers Squibb Description and Business Overview
Table 69. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 70. Bristol-Myers Squibb Product
Table 71. Bristol-Myers Squibb Recent Development
Table 72. Stem CentRx Corporation Information
Table 73. Stem CentRx Description and Business Overview
Table 74. Stem CentRx Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 75. Stem CentRx Product
Table 76. Stem CentRx Recent Development
Table 77. Biogen Idec Corporation Information
Table 78. Biogen Idec Description and Business Overview
Table 79. Biogen Idec Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 80. Biogen Idec Product
Table 81. Biogen Idec Recent Development
Table 82. Nordic Nanovector Corporation Information
Table 83. Nordic Nanovector Description and Business Overview
Table 84. Nordic Nanovector Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 85. Nordic Nanovector Product
Table 86. Nordic Nanovector Recent Development
Table 87. Millennium Corporation Information
Table 88. Millennium Description and Business Overview
Table 89. Millennium Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 90. Millennium Product
Table 91. Millennium Recent Development
Table 92. Biotest AG Corporation Information
Table 93. Biotest AG Description and Business Overview
Table 94. Biotest AG Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 95. Biotest AG Product
Table 96. Biotest AG Recent Development
Table 97. PDL BioPharma Corporation Information
Table 98. PDL BioPharma Description and Business Overview
Table 99. PDL BioPharma Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 100. PDL BioPharma Product
Table 101. PDL BioPharma Recent Development
Table 102. Progenics Pharmaceuticals Corporation Information
Table 103. Progenics Pharmaceuticals Description and Business Overview
Table 104. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 105. Progenics Pharmaceuticals Product
Table 106. Progenics Pharmaceuticals Recent Development
Table 107. Seattle Genetics Corporation Information
Table 108. Seattle Genetics Description and Business Overview
Table 109. Seattle Genetics Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 110. Seattle Genetics Product
Table 111. Seattle Genetics Recent Development
Table 112. Viventia Biotechnologies Corporation Information
Table 113. Viventia Biotechnologies Description and Business Overview
Table 114. Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 115. Viventia Biotechnologies Product
Table 116. Viventia Biotechnologies Recent Development
Table 117. AbGenomics Corporation Corporation Information
Table 118. AbGenomics Corporation Description and Business Overview
Table 119. AbGenomics Corporation Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 120. AbGenomics Corporation Product
Table 121. AbGenomics Corporation Recent Development
Table 122. Helix BioPharma Corporation Information
Table 123. Helix BioPharma Description and Business Overview
Table 124. Helix BioPharma Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 125. Helix BioPharma Product
Table 126. Helix BioPharma Recent Development
Table 127. Key Raw Materials Lists
Table 128. Raw Materials Key Suppliers Lists
Table 129. Cancer Antibody Drug Conjugates Customers List
Table 130. Cancer Antibody Drug Conjugates Distributors List
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Cancer Antibody Drug Conjugates Product Picture
Figure 2. Global Cancer Antibody Drug Conjugates Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Cancer Antibody Drug Conjugates Market Size 2017-2028 (US$ Million)
Figure 4. Global Cancer Antibody Drug Conjugates Sales 2017-2028 (K Pcs)
Figure 5. United States Cancer Antibody Drug Conjugates Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Cancer Antibody Drug Conjugates Market Size 2017-2028 (US$ Million)
Figure 7. United States Cancer Antibody Drug Conjugates Sales 2017-2028 (K Pcs)
Figure 8. United States Cancer Antibody Drug Conjugates Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Cancer Antibody Drug Conjugates Market Share in Global, in Volume (K Pcs) 2017-2028
Figure 10. Cancer Antibody Drug Conjugates Report Years Considered
Figure 11. Product Picture of First & Second Generation ADCs
Figure 12. Product Picture of Third Generation ADCs
Figure 13. Global Cancer Antibody Drug Conjugates Market Share by Type in 2022 & 2028
Figure 14. Global Cancer Antibody Drug Conjugates Sales in Value by Type (2017-2028) & (US$ Million)
Figure 15. Global Cancer Antibody Drug Conjugates Sales Market Share in Value by Type (2017-2028)
Figure 16. Global Cancer Antibody Drug Conjugates Sales by Type (2017-2028) & (K Pcs)
Figure 17. Global Cancer Antibody Drug Conjugates Sales Market Share in Volume by Type (2017-2028)
Figure 18. Global Cancer Antibody Drug Conjugates Price by Type (2017-2028) & (USD/Pcs)
Figure 19. United States Cancer Antibody Drug Conjugates Market Share by Type in 2022 & 2028
Figure 20. United States Cancer Antibody Drug Conjugates Sales in Value by Type (2017-2028) & (US$ Million)
Figure 21. United States Cancer Antibody Drug Conjugates Sales Market Share in Value by Type (2017-2028)
Figure 22. United States Cancer Antibody Drug Conjugates Sales by Type (2017-2028) & (K Pcs)
Figure 23. United States Cancer Antibody Drug Conjugates Sales Market Share in Volume by Type (2017-2028)
Figure 24. United States Cancer Antibody Drug Conjugates Price by Type (2017-2028) & (USD/Pcs)
Figure 25. Product Picture of Hospitals
Figure 26. Product Picture of Clinics
Figure 27. Product Picture of Others
Figure 28. Global Cancer Antibody Drug Conjugates Market Share by Application in 2022 & 2028
Figure 29. Global Cancer Antibody Drug Conjugates Sales in Value by Application (2017-2028) & (US$ Million)
Figure 30. Global Cancer Antibody Drug Conjugates Sales Market Share in Value by Application (2017-2028)
Figure 31. Global Cancer Antibody Drug Conjugates Sales by Application (2017-2028) & (K Pcs)
Figure 32. Global Cancer Antibody Drug Conjugates Sales Market Share in Volume by Application (2017-2028)
Figure 33. Global Cancer Antibody Drug Conjugates Price by Application (2017-2028) & (USD/Pcs)
Figure 34. United States Cancer Antibody Drug Conjugates Market Share by Application in 2022 & 2028
Figure 35. United States Cancer Antibody Drug Conjugates Sales in Value by Application (2017-2028) & (US$ Million)
Figure 36. United States Cancer Antibody Drug Conjugates Sales Market Share in Value by Application (2017-2028)
Figure 37. United States Cancer Antibody Drug Conjugates Sales by Application (2017-2028) & (K Pcs)
Figure 38. United States Cancer Antibody Drug Conjugates Sales Market Share in Volume by Application (2017-2028)
Figure 39. United States Cancer Antibody Drug Conjugates Price by Application (2017-2028) & (USD/Pcs)
Figure 40. North America Cancer Antibody Drug Conjugates Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 41. North America Cancer Antibody Drug Conjugates Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 42. U.S. Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 43. Canada Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 44. Europe Cancer Antibody Drug Conjugates Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 45. Europe Cancer Antibody Drug Conjugates Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 46. Germany Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 47. France Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 48. U.K. Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 49. Italy Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 50. Russia Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 51. Asia-Pacific Cancer Antibody Drug Conjugates Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 52. Asia-Pacific Cancer Antibody Drug Conjugates Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 53. China Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 54. Japan Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 55. South Korea Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 56. India Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 57. Australia Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. Taiwan Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. Indonesia Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. Thailand Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. Malaysia Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Philippines Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 63. Latin America Cancer Antibody Drug Conjugates Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 64. Latin America Cancer Antibody Drug Conjugates Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 65. Mexico Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 66. Brazil Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 67. Argentina Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 68. Middle East & Africa Cancer Antibody Drug Conjugates Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 69. Middle East & Africa Cancer Antibody Drug Conjugates Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 70. Turkey Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 71. Saudi Arabia Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 72. U.A.E Cancer Antibody Drug Conjugates Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 73. Cancer Antibody Drug Conjugates Value Chain
Figure 74. Cancer Antibody Drug Conjugates Production Process
Figure 75. Channels of Distribution
Figure 76. Distributors Profiles
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed